Systemic Lupus Erthematosus (SLE) Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting systemic lupus erthematosus (sle) clinical trials across 5 countries. Studies span Early Phase 1, Phase 1, Phase 2. Top locations include Hangzhou, Zhejiang, China, Bonn, North Rhine-Westphalia, Germany, Brisbane, Australia. Updated daily from ClinicalTrials.gov.


Systemic Lupus Erthematosus (SLE) Trials at a Glance

7 actively recruiting trials for systemic lupus erthematosus (sle) are listed on ClinicalTrialsFinder across 5 cities in 5 countries. The largest study group is Early Phase 1 with 2 trials, with the heaviest enrollment activity in Hangzhou, Bonn, and Brisbane. Lead sponsors running systemic lupus erthematosus (sle) studies include The Children's Hospital of Zhejiang University School of Medicine, Hinge Bio, and McGill University Health Centre/Research Institute of the McGill University Health Centre.

Browse systemic lupus erthematosus (sle) trials by phase

Treatments under study

About Systemic Lupus Erthematosus (SLE) Clinical Trials

Looking for clinical trials for Systemic Lupus Erthematosus (SLE)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Lupus Erthematosus (SLE) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Lupus Erthematosus (SLE) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

2-HOBA in Systemic Lupus Erythematosus

Systemic Lupus Erthematosus (SLE)
Vanderbilt University Medical Center42 enrolled1 locationNCT07225543
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

VasculitisSystemic Lupus Erthematosus (SLE)Rheumatic Diseases+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre100 enrolled1 locationNCT07278609
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 1

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Lupus Nephritis (LN)Systemic Lupus Erthematosus (SLE)Extra-renal Lupus (ERL)
Hinge Bio30 enrolled1 locationNCT07491900
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+10 more
University of Bonn120 enrolled1 locationNCT07150000